IL6 and osteoporosis: Some pro-inflammatory cytokines, such as Tumor Necrosis Factor-alpha (TNF-α) or interleukin 6 (IL-6), may exert an inhibitory effect on osteoprotegerin (OPG) increasing Receptor Activator for Nuclear Factor κ B Ligand (RANKL) concentrations, and consequently, increasing the osteoclastic activity, bone resorption and the risk of osteoporosis incidence [10, 11].